W Satmary1, C H Holschneider2, L L Brunette3, S Natarajan4. 1. Department of Obstetrics & Gynecology, Kaiser Permanente Medical Center, Panorama City, CA 91402, United States. Electronic address: Wendy.A.Satmary@kp.org. 2. Department of Obstetrics & Gynecology, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States; David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, United States. 3. LAC+USC Medical Center, Keck School of Medicine, University of Southern California, 90033, United States. 4. Department of Pathology, Kaiser Permanente Medical Center, Los Angeles, CA 90027, United States.
Abstract
OBJECTIVE: We studied a large population of women with high-grade vulvar intraepithelial neoplasia (VIN) in order to identify patient and treatment-related risk factors for recurrence and progression to cancer. METHODS: For this retrospective cohort study of women with a histologic diagnosis of VIN within Southern California Permanente Medical Group between 1995 and 2007 medical records were reviewed; clinical, demographic and pathologic data were collected. Statistical analyses included Chi-squared and Student's t-tests, univariate and multivariate logistic regression, and cumulative incidence analysis. RESULTS: 914 patients with high-grade VIN were identified; 784 met inclusion criteria. We found 26.3% recurrences among treated women, with 2.2% progression to cancer (8.2% among those with recurrence). Risk factors for recurrence on multivariate analysis were: age >50years (OR, 1.44; 95%CI 1.01-2.07), immunosuppression (OR 2.08; 95%CI 1.42-3.06), metasynchronous VAIN or CIN (OR 1.76; 95%CI 1.08-2.88) in addition to margin status (OR 8.17; 95%CI 4.60-14.51) and adjacent LSA (OR 9.91; 95%CI 1.53-31.32) or HPV (OR 2.15; 95%CI 1.13-3.37) with excisional treatment. Recurrence rates did not differ significantly by smoking status and treatment modalities. Median time to recurrence was 16.9months; 25% had late recurrences (44-196months). Cumulative incidence analyses of time to recurrence shows a significantly higher risk among patients over age 50 (log-rank p=0.0031). CONCLUSION: We identified independent risk factors for recurrence including age >50years, immunosuppression, metasynchronous vaginal or intraepithelial neoplasia, positive excision margins, and adjacent lichen sclerosus or human papilloma-virus. Regardless of treatment modality, 25% of recurrences occurred late, highlighting the need for long-term surveillance in women treated for VIN.
OBJECTIVE: We studied a large population of women with high-grade vulvar intraepithelial neoplasia (VIN) in order to identify patient and treatment-related risk factors for recurrence and progression to cancer. METHODS: For this retrospective cohort study of women with a histologic diagnosis of VIN within Southern California Permanente Medical Group between 1995 and 2007 medical records were reviewed; clinical, demographic and pathologic data were collected. Statistical analyses included Chi-squared and Student's t-tests, univariate and multivariate logistic regression, and cumulative incidence analysis. RESULTS: 914 patients with high-grade VIN were identified; 784 met inclusion criteria. We found 26.3% recurrences among treated women, with 2.2% progression to cancer (8.2% among those with recurrence). Risk factors for recurrence on multivariate analysis were: age >50years (OR, 1.44; 95%CI 1.01-2.07), immunosuppression (OR 2.08; 95%CI 1.42-3.06), metasynchronous VAIN or CIN (OR 1.76; 95%CI 1.08-2.88) in addition to margin status (OR 8.17; 95%CI 4.60-14.51) and adjacent LSA (OR 9.91; 95%CI 1.53-31.32) or HPV (OR 2.15; 95%CI 1.13-3.37) with excisional treatment. Recurrence rates did not differ significantly by smoking status and treatment modalities. Median time to recurrence was 16.9months; 25% had late recurrences (44-196months). Cumulative incidence analyses of time to recurrence shows a significantly higher risk among patients over age 50 (log-rank p=0.0031). CONCLUSION: We identified independent risk factors for recurrence including age >50years, immunosuppression, metasynchronous vaginal or intraepithelial neoplasia, positive excision margins, and adjacent lichen sclerosus or human papilloma-virus. Regardless of treatment modality, 25% of recurrences occurred late, highlighting the need for long-term surveillance in women treated for VIN.
Authors: Mario Preti; Elmar Joura; Pedro Vieira-Baptista; Marc Van Beurden; Federica Bevilacqua; Maaike C G Bleeker; Jacob Bornstein; Xavier Carcopino; Cyrus Chargari; Margaret E Cruickshank; Bilal Emre Erzeneoglu; Niccolò Gallio; Debra Heller; Vesna Kesic; Olaf Reich; Colleen K Stockdale; Bilal Esat Temiz; Linn Woelber; François Planchamp; Jana Zodzika; Denis Querleu; Murat Gultekin Journal: J Low Genit Tract Dis Date: 2022-06-21 Impact factor: 3.842
Authors: Helen C Stankiewicz Karita; Kirsten Hauge; Amalia Magaret; Constance Mao; Jeffrey Schouten; Verena Grieco; Long Fu Xi; Denise A Galloway; Margaret M Madeleine; Anna Wald Journal: JAMA Netw Open Date: 2019-04-05
Authors: Giulia Wanka; Elisa Schmoeckel; Doris Mayr; Sophie Fuerst; Christina Kuhn; Sven Mahner; Julia Knabl; Maria Margarete Karsten; Christian Dannecker; Helene H Heidegger; Aurelia Vattai; Udo Jeschke; Julia Jueckstock Journal: Int J Mol Sci Date: 2020-12-05 Impact factor: 5.923
Authors: Noor Alida Maria Bakker; Jossie Rotman; Joost H van den Berg; Nienke E van Trommel; Marc van Beurden; Henry J Maa Zijlmans; Maartje van Ruiten; Sanne Samuels; Bastiaan Nuijen; Jos Beijnen; Karin De Visser; John Haanen; Ton Schumacher; Tanja D de Gruijl; Ekaterina S Jordanova; Gemma G Kenter Journal: J Immunother Cancer Date: 2021-08 Impact factor: 13.751